C3a and C5b-9 Differentially Predict COVID-19 Progression and Outcome
Maria G. Detsika,
Elpida Diamanti,
Kleio Ampelakiotou,
Edison Jahaj,
Stamatis Tsipilis,
Nikolaos Athanasiou,
Ioanna Dimopoulou,
Stylianos E. Orfanos,
Alexandra Tsirogianni,
Anastasia Kotanidou
Affiliations
Maria G. Detsika
1st Department of Critical Care Medicine & Pulmonary Services, GP Livanos and M Simou Laboratories, Evangelismos Hospital, National and Kapodistrian University of Athens, 10675 Athens, Greece
Elpida Diamanti
1st Department of Critical Care Medicine & Pulmonary Services, GP Livanos and M Simou Laboratories, Evangelismos Hospital, National and Kapodistrian University of Athens, 10675 Athens, Greece
Kleio Ampelakiotou
Department of Immunology and Histocompatibility, Evangelismos General Hospital, 10676 Athens, Greece
Edison Jahaj
1st Department of Critical Care Medicine & Pulmonary Services, GP Livanos and M Simou Laboratories, Evangelismos Hospital, National and Kapodistrian University of Athens, 10675 Athens, Greece
Stamatis Tsipilis
1st Department of Critical Care Medicine & Pulmonary Services, GP Livanos and M Simou Laboratories, Evangelismos Hospital, National and Kapodistrian University of Athens, 10675 Athens, Greece
Nikolaos Athanasiou
1st Department of Critical Care Medicine & Pulmonary Services, GP Livanos and M Simou Laboratories, Evangelismos Hospital, National and Kapodistrian University of Athens, 10675 Athens, Greece
Ioanna Dimopoulou
1st Department of Critical Care Medicine & Pulmonary Services, GP Livanos and M Simou Laboratories, Evangelismos Hospital, National and Kapodistrian University of Athens, 10675 Athens, Greece
Stylianos E. Orfanos
1st Department of Critical Care Medicine & Pulmonary Services, GP Livanos and M Simou Laboratories, Evangelismos Hospital, National and Kapodistrian University of Athens, 10675 Athens, Greece
Alexandra Tsirogianni
Department of Immunology and Histocompatibility, Evangelismos General Hospital, 10676 Athens, Greece
Anastasia Kotanidou
1st Department of Critical Care Medicine & Pulmonary Services, GP Livanos and M Simou Laboratories, Evangelismos Hospital, National and Kapodistrian University of Athens, 10675 Athens, Greece
SARS-CoV-2 infection may result in severe pneumonia leading to mechanical ventilation and intensive care (ICU) treatment. Complement activation was verified in COVID-19 and implicated as a contributor to COVID-19 pathogenesis. This study assessed the predictive potential of complement factors C3a and C5b-9 for COVID-19 progression and outcome. We grouped 80 COVID-19 patients into severe COVID-19 patients (n = 38) and critically ill (n = 42) and subdivided into non-intubated (n = 48) and intubated (n = 32), survivors (n = 57) and non-survivors (n = 23). Results: A significant increase for C3a and C5b-9 levels was observed between: severely and critically ill patients (p p p p p p p p p p p p = NS). Combining the two markers revealed a powerful prediction tool for ICU admission (AUC = 0.773, p p p < 0.001). C3a and C5b-9 may be considered as prognostic tools separately or in combination for the progression and outcome of COVID-19.
